These manifested that CBFB-MYH11 fusion took the shape of a neoantigen, which had potential as a target for immunotherapy and provided evidence of principle for fusion-directed T cell immunotherapy of AML. This evidence concerns the gene MYH11 and acute myeloid leukemia.